Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alisertib (Primary)
  • Indications Adult T-cell leukaemia-lymphoma; Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 09 Mar 2016 According to ClinicalTrials.gov record Primary endpoint of Aurora kinase A expression has been shifted in the other outcomes field; Primary endpoint of Objective Response Rate with time frame of 1 year has been added; Also Primary endpoint of overall survival has been changed to secondary
    • 08 Oct 2015 Status changed from active, no longer recruiting to completed as full results are published in JCO 2015
    • 26 Jun 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top